

Supplementary Figure 6. Sirt1 activator Resveratrol reverses deleterious effects of IL-1 β on Bmal1 promoter activation. Bmal1 promoter activity assessed using stable-transfected Bmal1:luciferase (Bmal1:LUC) reporter expressing INS-832/13 β -cells exposed for 24 h to IL-1 β (0.1-5 ng/ml) with or without co-treatment with Sirt1 chemical agonist Resveratrol (10 and 50 μ M). Values are mean \pm SEM (n=6 independent experiments per given condition) and *P<0.05 denotes statistical significance vs. untreated.